

# 1 **Comprehensive Druggable Genome-Wide Mendelian Randomization** 2 **Reveals Therapeutic Targets for Kidney Diseases**

3 **Zhihang Su<sup>1</sup>, Qijun Wan<sup>1\*</sup>**

4 <sup>1</sup>Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of  
5 Shenzhen University, Shenzhen, China

6 **\* Correspondence:**

7 Qijun Wan (Email: [yyuan2224@sina.com](mailto:yyuan2224@sina.com))

8

9 Word Count:

10 Abstract: 328 words

11 Text (excluding references): 3120 words

12 **Keywords: Membranous nephropathy, Mendelian randomization, druggable genes,**  
13 **Therapeutic targets, genome-wide association study (GWAS).**

## 14 **Abstract**

15 Background:

16 Kidney diseases, including membranous nephropathy (MN), IgA nephropathy (IgAN), and chronic  
17 kidney disease (CKD), pose significant global health challenges due to their high prevalence and  
18 severe outcomes. There is still an urgent need to discover new targets for treating kidney diseases.  
19 Mendelian randomization (MR) has been widely used to repurpose licensed drugs and discover novel  
20 therapeutic targets. Thus, we aimed to identify novel therapeutic targets for Kidney diseases and  
21 analyze their pathophysiological mechanisms and potential side effects.

22 Methods:

23 Integrated with currently available druggable genes, Summary-data-based MR (SMR) analysis was  
24 conducted to estimate the causal effects of blood expression quantitative trait loci (eQTLs) on kidney  
25 diseases. A study was replicated using distinct blood eQTL and diseases genome-wide association  
26 study (GWAS) data sources to validate the identified genes. The eQTL data was obtained from  
27 eQTLGen and GTEx v8.0, with sample sizes of 31,684 and 15,201, respectively. The data on kidney  
28 diseases was sourced from the Kiryluk Lab, CKDgen, and the FinnGen consortium, with sample sizes  
29 ranging from 7,979 to 412,181. Subsequently, reverse two-sample MR and colocalization analysis  
30 were employed for further validation. Finally, the potential side effects of the identified key genes in  
31 treating kidney diseases were assessed using phenome-wide MR and mediation MR.

32 Results:

33 After correcting for the false discovery rate, a total of 20, 23, and 6 unique potential genes were  
34 found to have causal relationships with MN, IgAN, and CKD, respectively. Among them, MN  
35 showed validated associations with one gene (HCG18), IgAN demonstrated associations with four

36 genes (AFF3, CYP21A2, DPH3, HLA-DRB5), and chronic kidney disease (CKD) displayed an  
37 association with one gene (HLA-DQB1-AS1). Several of these key genes are druggable genes.  
38 Further phenome-wide MR analysis revealed that certain genes may be associated with diabetes, fat  
39 metabolism, and infectious diseases, suggesting that these factors could potentially serve as  
40 mediators.

41 Conclusions:

42 This study presents genetic evidence that supports the potential therapeutic benefits of targeting these  
43 key genes for treating kidney diseases. This is significant in prioritizing the development of drugs for  
44 kidney diseases.

## 45 **1 Introduction**

46 Kidney diseases, including membranous nephropathy (MN), IgA nephropathy (IgAN), and chronic  
47 kidney disease (CKD), pose significant global health challenges due to their high prevalence and  
48 severe outcomes. MN, characterized by the deposition of immune complexes in the glomerular  
49 basement membrane, often leads to nephrotic syndrome and progressive renal failure if untreated(1).  
50 IgAN, the most common glomerulonephritis worldwide, is marked by the accumulation of IgA in the  
51 glomeruli, causing inflammation and potentially advancing to end-stage renal disease (ESRD)(2).  
52 CKD, defined by the gradual loss of kidney function over time, affects millions and significantly  
53 increases the risk of cardiovascular disease and mortality(3). Despite advancements in understanding  
54 the pathophysiology of these diseases, effective treatments remain limited. Current therapeutic  
55 strategies primarily focus on managing symptoms and slowing disease progression, but they do not  
56 halt or reverse kidney damage. For instance, the treatment of MN and IgAN often involves  
57 immunosuppressive therapies, which can have substantial side effects and variable efficacy.  
58 Similarly, CKD management revolves around controlling hypertension and diabetes, delaying  
59 progression rather than curing the disease. The identification of novel therapeutic targets is crucial to  
60 developing more effective treatments. With advances in genomics, proteomics, and bioinformatics,  
61 there is an unprecedented opportunity to uncover molecular pathways involved in kidney disease  
62 pathogenesis. Targeting these pathways could lead to innovative therapies that address the underlying  
63 causes of kidney damage rather than merely alleviating symptoms. This approach holds promise for  
64 improving patient outcomes and quality of life, highlighting the importance of ongoing research in  
65 this field.

66 Mendelian randomization (MR) is a powerful epidemiological method that leverages genetic variants  
67 as instrumental variables to assess the causal effects of modifiable risk factors on disease  
68 outcomes(4). By utilizing the random assortment of genes from parents to offspring, MR mimics the  
69 conditions of a randomized controlled trial, thereby minimizing confounding and reverse causation  
70 issues that often plague observational studies(5,6). This technique has gained prominence in  
71 identifying potential drug targets by providing insights into the causal relationships between  
72 biomarkers, risk factors, and disease outcomes(7,8).

73 In recent years, MR has been increasingly applied to drug discovery and development. By correlating  
74 genetic variants that influence drug target genes with clinical outcomes, MR can validate the  
75 therapeutic potential of specific targets before costly clinical trials are initiated. For instance, the use  
76 of MR has facilitated the identification of novel therapeutic targets for cardiovascular diseases by  
77 confirming the causal role of lipid levels and inflammatory markers in disease progression(9,10).

78 Similarly, MR studies have highlighted the potential of targeting specific metabolic pathways in  
79 treating diabetes and other metabolic disorders(11,12).

80 The application of MR in drug target discovery is not without challenges, including the need for  
81 robust genetic instruments and comprehensive datasets. However, integrating MR with advanced  
82 genomic technologies and large-scale biobanks holds great promise for the future of precision  
83 medicine. By enhancing our ability to identify and validate causal relationships between potential  
84 drug targets and disease outcomes, MR can accelerate the development of effective and safe  
85 therapeutics, ultimately improving patient care.

## 86 **2 Methods**

87 This study was conducted according to the reporting guidelines outlined by the Strengthening the  
88 Reporting of Observational Studies in Epidemiology (STROBE) initiative.

### 89 **2.1 Identification of druggable genes**

90 The information regarding druggable genes was obtained from the Drug-Gene Interaction Database  
91 (DGIdb V.5.0.6) and the latest review on the "druggability" of genes(13). DGIdb provides  
92 comprehensive information on drug-gene interactions and druggable genes from various sources,  
93 including publications, databases, and other web resources(14). For this study, we retrieved the  
94 "categories" data from DGIdb, which was released in February 2022. This dataset contains a  
95 comprehensive list of druggable genes mapped to Entrez genes in DGIdb. Furthermore, we  
96 supplemented our findings with additional gene listings of druggable genes from the review  
97 conducted by Finan et al.

### 98 **2.2 Expression quantitative trait loci**

99 The blood eQTL dataset used in this study was obtained from eQTLGen (<https://eqtlgen.org/>). The  
100 dataset comprises blood samples from 31,684 individuals of European ancestry who were in good  
101 health(15). It covers cis-eQTLs of 16,987 genes. We exclusively considered cis-eQTL results that  
102 exhibited high significance (false discovery rate (FDR) < 0.05) and also incorporated allele frequency  
103 information. We identified genetic variants located within a 1000 kb range on both sides of the  
104 coding sequences (cis) that exhibited a strong association with gene expression. These variants were  
105 extracted using eQTL summary statistics obtained from the eQTLGen Consortium. Nonetheless, it  
106 should be noted that eQTLGen does not encompass variants linked to gene expression levels on the  
107 X and Y chromosomes, as well as mtDNA. Further details regarding the data can be found in the  
108 original publication. Additionally, to validate the obtained results, we employed the whole-blood cis-  
109 eQTL data from the Genotype-Tissue Expression (GTEx) project, specifically GTEx V.8  
110 (<https://gtexportal.org/home/datasets>), which consisted of 15,201 samples.

### 111 **2.3 Kidney diseases data**

112 The primary source of discovery data for this study is the MN and IgAN databases provided by the  
113 Kiryluk Lab(16,17), along with the CKD database provided by the FinnGen Consortium. To validate  
114 our findings, we additionally utilized the databases from the FinnGen Consortium, CKDgen, and  
115 other sources. Regarding the Kiryluk Lab data, all MN cases were diagnosed utilizing the gold  
116 standard method of renal biopsy, whereas all IgAN cases were defined through dominant mesangial  
117 IgA staining on renal biopsy immunofluorescence. Cases potentially associated with secondary  
118 causes (e.g., Hepatitis, autoimmune, or malignant diseases) were excluded to uphold study rigor.

119 CKDgen's research covers chronic kidney disease (CKD), which is defined by the criteria of  
120 eGFR<sub>crea</sub> < 60 ml/min/1.73m<sup>2</sup> and includes conditions such as urinary albumin-to-creatinine ratio  
121 (UACR > 30 mg/g) and gout(18,19). As the study samples are predominantly sourced from the  
122 general population, the research did not primarily focus on severe CKD and severe proteinuria. The  
123 analysis concentrates on cases with eGFR > 15 ml/min/1.73m<sup>2</sup> and excludes patients receiving  
124 dialysis treatment.

## 125 **2.4 Mendelian randomization**

126 The MR method necessitates the fulfillment of three fundamental assumptions. To broaden the  
127 scope of MR, we performed a summary-data-based MR approach that estimates pleiotropic  
128 associations between genetic determinants of traits (e.g., gene expression, DNA methylation, or  
129 protein abundance as exposures) and our target complex traits, including MN, IgAN, and CKD. The  
130 heterogeneity-independent instruments (HEIDI) test is one of the sensitivity analysis techniques  
131 utilizing an external reference to estimate linkage disequilibrium (LD). Following false discovery rate  
132 (FDR) correction, genes exhibiting SMR < 0.05 and HEIDI test > 0.05 are deemed to possess causal  
133 relationships. Furthermore, we examine the observed effect sizes (OR values) to discern their roles as  
134 risk or protective factors. Subsequent to the completion of the SMR analysis, we conducted  
135 additional sensitivity analysis employing the Two-sample MR (TSMR) approach, encompassing  
136 inverse variance weighted (IVW) and the Wald ratio. Each method relies on distinct assumptions  
137 regarding the validity of instrumental variables to compute estimates of causal effects, thus  
138 furnishing robust evidence for our findings. In conducting TSMR, we employ data from the 1000  
139 Genomes project (HG19/GRCh37) as a substitute in cases where effect allele frequency data is  
140 missing.

## 141 **2.5 Phenome-wide MR and mediation MR**

142 Using data from the UK Biobank as the outcome and key genes as the exposure, we employed  
143 phenome-wide Mendelian randomization (MR) to identify phenotypes associated with the key genes,  
144 potentially indicating comorbidity relationships with kidney diseases. Moreover, to identify  
145 intermediary factors associated with kidney diseases, we conducted two-sample MR analysis using  
146 key genes as the exposure, UK Biobank data as the mediator, and kidney diseases as the outcome.

## 147 **2.6 Bayesian colocalization analysis**

148 Occasionally, a single nucleotide polymorphism (SNP) may be situated within multiple gene regions.  
149 In such instances, if the SNP contains information on the expression of quantitative trait loci (QTL)  
150 for two or more distinct genes, its influence on kidney diseases (MN, IgAN, and CKD) will reflect a  
151 combination of various genes. Co-localization analysis is employed to validate the presence of shared  
152 causal genetic variations between kidney diseases and eQTL. Briefly, we conducted the  
153 colocalization analysis to investigate the co-localization of kidney disease risk and SNP within ±100  
154 kb of the transcription start site (TSS) of each gene in eQTL, focusing on significant MR (Mendelian  
155 randomization) results from the discovery phase ( $P_1 = 1 \times 10^{-5}$ ,  $P_2 = 1 \times 10^{-5}$ , and  $P_{12} = 1 \times 10^{-5}$ ).  $P_1$   
156 denotes the probability of a significant eQTL association with the provided SNP,  $P_2$  signifies the  
157 probability of the given SNP being associated with kidney disease, and  $P_{12}$  indicates the probability  
158 of the given SNP being associated with both kidney disease and eQTL outcomes. The researchers  
159 evaluated five hypotheses, and posterior probabilities (PP) are utilized to quantify the level of support  
160 for each hypothesis, categorized as PPH0 to PPH4, with a specific emphasis on PPH3 and PPH4.  
161 PPH3 represents the co-localization of gene expression and kidney disease, demonstrating distinct  
162 causal variations within the same gene locus, whereas PPH4 indicates the co-localization of gene

163 expression and kidney disease, manifesting shared causal variations. Due to the limited power of co-  
164 localization analysis, we confined our analysis to genes that surpassed a threshold of  $PPH3+PPH4 \geq$   
165 0.5 (0.5 to 0.8 indicating moderate strength,  $>0.8$  indicating high strength).

## 166 **2.7 Functional Enrichment Analysis**

167 The functions of genes and potential signaling pathways associated with tumorigenesis and  
168 progression in kidney diseases were explored using the Metascape database (v3.5.20240101). By  
169 utilizing these selected functional sets in Metascape, our aim was to gain insights into the molecular  
170 functions, biological processes, pathways, and structural complexes associated with the genes in our  
171 dataset. Additionally, the Signature Module sets enabled us to explore cellular signatures associated  
172 with cell types, chemical and genetic perturbations, immunological signatures, and oncogenic  
173 signatures. The Miscellaneous sets provided information on transcription factor targets and gene-  
174 disease associations sourced from trusted databases, including TRRUST, PaGenBase, and  
175 DisGeNET. Furthermore, the L1000 sets allowed us to examine the effects of genetic perturbations,  
176 compounds, cDNA, and ligands. Lastly, we explored the vaccine response signatures, with a  
177 particular focus on COVID-related signatures, to gain insights into the immune response associated  
178 with our target genes. Through this comprehensive analysis, our aim was to uncover potential  
179 functional mechanisms, pathways, and interactions relevant to our target of interest. Gene Ontology  
180 (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were  
181 conducted. All genes that exhibited significant alterations after correction were included in this  
182 analysis. The GO analysis was categorized into three sections: BP (biological process), CC (cellular  
183 component), and MF (molecular function). A P-value below 0.05 was considered statistically  
184 significant.

## 185 **3 Results**

186 We successfully identified multiple causal associations between gene expression and kidney diseases  
187 in the blood through SMR tests. To control for type I errors across the entire genome, we conducted  
188 false discovery rate (FDR) correction, which revealed robust evidence of associations ( $FDR < 0.05$ ).  
189 Subsequently, we performed HEIDI tests ( $P > 0.05$ ) to explore whether these associations resulted  
190 from shared causal variants rather than pleiotropy. To support our findings, we conducted sensitivity  
191 analyses using other MR methods that are based on similar assumptions, demonstrating consistent  
192 outcomes. Additionally, to address confounding factors, we conducted a colocalization analysis,  
193 which assessed the posterior probability of shared causal variation ( $PPH4$ ) between gene expression  
194 and kidney diseases, employing a threshold of  $>0.50$ . Additionally, we replicated our findings by  
195 performing additional analyses utilizing other GWAS studies. The identified genes were classified  
196 into four distinct target groups based on SMR, TSMR, colocalization analysis, and external  
197 replication results.

198 Genes with an FDR-corrected SMR-P value  $< 0.05$  and a HEIDI test result  $> 0.05$  were considered  
199 essential criteria and classified as tier 1 targets when supported by TSMR, colocalization, and  
200 replication. Genes supported by any two of TSMR, colocalization, and replication were classified as  
201 tier 2 targets. Genes supported by any one of TSMR, colocalization, or replication were classified as  
202 tier 3 targets. The remaining genes were classified as tier 4 targets.

203 Following the aforementioned principles, we identified a primary target (HCG18) and multiple  
204 secondary targets associated with MN. Moreover, we identified four primary targets (AFF3,  
205 CYP21A2, DPH3, HLA-DRB5) and several secondary targets associated with IgAN. Additionally,  
206 we identified various secondary targets associated with CKD (Table 1). In the case of MN, a decrease



207 of 1 standard deviation (SD) in HCG18 expression was significantly associated with an 82%  
208 reduction in risk (OR: 0.18, 95% CI: 0.08-0.43,  $P^{\text{SMR}} = 9.79 \times 10^{-5}$ ). Regarding IgAN, an increase of 1  
209 SD in AFF3 expression was linked to a 46% reduced risk (OR: 0.54, 95% CI: 0.39-0.74,  $P^{\text{SMR}} =$   
210  $1.64 \times 10^{-4}$ ). Similarly, an increase of 1 SD in CYP21A2 expression was associated with a 42%  
211 reduced risk (OR: 0.58, 95% CI: 0.45-0.76,  $P^{\text{SMR}} = 5.53 \times 10^{-5}$ ), an increase of 1 SD in DPH3  
212 expression was correlated with a 27% reduced risk (OR: 0.73, 95% CI: 0.66-0.80,  $P^{\text{SMR}} = 3.89 \times 10^{-$   
213  $11$ ), and an increase of 1 SD in HLA-DRB5 expression was linked to a 26% reduced risk (OR: 0.74,  
214 95% CI: 0.43-0.86,  $P^{\text{SMR}} = 8.54 \times 10^{-5}$ ). The reverse TSMR analysis revealed an inverse relationship  
215 between IgAN and only HLA-DPA1, HVCN1, and EHMT2, while no associations were found for  
216 the remaining targets in kidney diseases.

### 217 **3.1 Phewas**

218 Through comprehensive phenotypic Mendelian randomization, we uncovered a range of diseases and  
219 phenotypes associated with kidney disease. These diseases and phenotypes may exhibit comorbidity  
220 with kidney disease. Moreover, employing a two-step approach, we identified diabetes, lipid  
221 metabolism, and other factors as potential pivotal mediators that influence kidney disease via genetic  
222 pathways.

### 223 **3.2 Functional Enrichment Analysis**

224 Pathways associated with key genes were identified through functional enrichment analysis. The  
225 AKT gene, CD4-positive dendritic cells, the immunoreceptor signaling pathway (UPG0:0002429),  
226 SATO-mediated methylation-induced silencing in pancreatic cancer, KRIGE's response to  
227 TOSEDOSTAT after 24 hours, and the carboxylic acid metabolism process may be associated with  
228 MN through key genes. Th17 cell differentiation and lipid metabolism may be associated with IgAN  
229 through key genes. Differences or upregulation between TARTE cells, plasma cells, and plasmablasts  
230 under specific conditions or treatments may be associated with CKD.

## 231 **4 Discussion**

232 To the best of our knowledge, this study represents the pioneering attempt to integrate blood  
233 genomics data with SMR, TSMR, Bayesian colocalization, phenotype scanning, KEGG, GO pathway  
234 analysis, and PPI analysis methods. Multiple databases were utilized to uncover and validate the  
235 potential roles of specific genes in MN, IgAN, and CKD. Through genetic prediction, we established  
236 a causal relationship between HCG18 and MN, AFF3, CYP21A2, DPH3, HLA-DRB5 and IgAN,  
237 and HLA-DQB1-AS1 and CKD (the highest-level targets discovered for each disease are listed here).  
238 After conducting a series of analyses, we ultimately identified the aforementioned genes as high-  
239 priority potential drug targets for kidney diseases. According to the target principles mentioned  
240 earlier, we believe these genes can function as potential drug targets for the treatment of kidney  
241 diseases, and several of them are druggable.

242 By utilizing SMR and employing various validation methods, we have newly identified several  
243 promising genes, thus enhancing their potential as therapeutic intervention targets. Therefore, to  
244 determine innovative targets for drug interventions in kidney diseases, we conducted comprehensive  
245 analyses to assess the causal relationships of genes. Causal relationships identified through MR may  
246 involve reverse causality, horizontal pleiotropy, or genetic confounding induced by LD. Therefore, in  
247 this study, we employed IVs exhibiting strong correlations with the genes, utilized the HEIDI test to  
248 estimate LD, and excluded IVs that exhibited evidence of linkage disequilibrium during MR  
249 implementation. Reverse Mendelian randomization analysis uncovered bidirectional causal

250 relationships between HLA-DPA1, HVCN1, EHMT2, and IgAN. Additionally, Bayesian  
251 colocalization was utilized to mitigate bias introduced by LD (24). Employing a posterior probability  
252 threshold of 0.5, it was deemed to possess moderate to high colocalization strength, and we identified  
253 all genes that exhibited SMR positivity. Nevertheless, these associations alone do not fully elucidate  
254 the connections between the identified genes and kidney diseases. Additionally, we performed  
255 phenotype scanning analyses of the instrumental variables utilized in the MR analysis to address  
256 confounding factors. Thus, the aforementioned genes have the potential to serve as drug targets for  
257 kidney diseases, with a particular focus on Tier 1 targets.

## 258 Membranous Nephropathy

259 HLA Complex Group 18 (HCG18) is a long non-coding RNA gene. For HCG18 and MN, there are  
260 some indications of a potential relationship, although it is not well-established. Research has shown  
261 that long non-coding RNAs (lncRNAs), including HCG18, are involved in various biological  
262 processes and diseases, including cancer, COVID-19 infections, and potentially other complex  
263 conditions like nephropathy(20–22). However, specific studies directly linking HCG18 to MN are  
264 sparse. One study suggests that lncRNAs like HCG18 could regulate immune responses and cellular  
265 processes that might be relevant to diseases like MN, but conclusive evidence is lacking.

## 266 IgA nephropathy

267 AFF3, also known as ALF Transcription Elongation Factor 3, is a protein-coding gene that encodes a  
268 nuclear transcriptional activation factor with tissue-restricted expression, primarily in lymphoid  
269 tissues. AFF3 is associated with diseases such as Familial Syndrome and Intellectual Developmental  
270 Disorder, specifically X-linked 109. Furthermore, it is suggested that this gene may contribute to  
271 lymphoid development and tumor formation. CYP21A2, also known as Cytochrome P450 Family 21  
272 Subfamily A Member 2, is a protein-coding gene. CYP21A2 is associated with diseases such as  
273 Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency and Classical Congenital Adrenal  
274 Hyperplasia, both caused by 21-hydroxylase deficiency. HLA-DRB5, a member of the Major  
275 Histocompatibility Complex Class II, is a protein-coding gene that encodes the DR Beta 5 subunit.  
276 HLA-DRB5 is associated with diseases such as Pityriasis Rosea and Systemic Lupus Erythematosus.  
277 It involves related pathways, including TCR Signaling and Phosphorylation of CD3 and TCR zeta  
278 chains. DPH3, also called Diphthamide Biosynthesis 3, is a protein-coding gene. DPH3 is associated  
279 with diseases such as Diphtheria and Melanotic Schwannoma. It involves related pathways such as  
280 Protein Metabolism,  $\gamma$ -carboxylation, hypusine formation, and arylsulfatase activation.

## 281 Chronic Kidney Disease

282 HLA-DQB1-AS1, an RNA gene classified as a long non-coding RNA (lncRNA), It has been  
283 suggested to be associated with Osteoarthritis and Muscle Atrophy.

284 Our study has several limitations. Firstly, the blood genomic data used in our analysis were sourced  
285 from two distinct studies that may have utilized varying measurement standards. However, we chose  
286 a database with a large sample size as the discovery cohort, and another one as the validation cohort.  
287 Secondly, during the validation process using different databases, certain genes did not produce  
288 results, resulting in missing data. Missing data does not imply insignificant findings; instead, it  
289 signifies unknown information. Thirdly, the data utilized in our experiments solely represent the  
290 European population, necessitating further research to extend the generalizability of our findings to  
291 other ethnicities. Additionally, the precise mechanisms underlying these genes and kidney diseases  
292 are still unknown. It is essential to acknowledge that unvalidated data analysis may encompass

293 aspects necessitating experimental verification, thereby enabling the achievement of objectives  
294 beyond the scope of data analysis alone. Our data can be utilized in future research to validate drug  
295 targets. Enhancing our comprehension of the genetic regulation of drug targets and the circulating  
296 levels of biomarkers may improve drug interventions and clinical trials.

## 297 **5 Data availability**

298 eQTLs data was derived via public research(23), and MN data was retrieved from Kiryluk Lab(16).  
299 We used R language version 4.3.0 for our analysis. In R language, we utilized the "coloc  
300 (<https://github.com/chr1swallace/coloc.git>)" and "TwoSampleMR  
301 (<https://github.com/MRCIEU/TwoSampleMR.git>)" and "locuscompare" packages for our  
302 analysis(24).

## 303 **6 Conflict of Interest**

304 The authors declare that the research was conducted without any commercial or financial  
305 relationships that could potentially create a conflict of interest.

## 306 **7 Ethic**

307 The data utilized in this analysis were obtained from publicly accessible databases. All of the data  
308 have been de-identified and received ethical approval from the appropriate ethics committee.  
309 Consequently, this study does not necessitate individual ethical approval.

## 310 **8 Author Contributions**

311 Zhihang Su and Qijun Wan jointly accomplished all efforts. Rui Xue, Jiaqi Liu, Liling Wu, and Yuan  
312 Cheng contributed to revising and refining the article.

## 313 **9 Funding**

314 Shenzhen Key Medical Discipline Construction Fund (SZXK009) and SZSM202211013.

## 315 **10 Acknowledgments**

316 Sincere thanks to all participants who participated in producing the public database.

## 317 **11 References**

- 318 1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017 Jun  
319 7;12(6):983–97.
- 320 2. Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al. IgA nephropathy. Nat Rev  
321 Dis Primer. 2023 Nov 30;9(1):67.
- 322 3. Drawz P, Rahman M. Chronic kidney disease. Ann Intern Med. 2015 Jun 2;162(11):ITC1-16.
- 323 4. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in  
324 epidemiological studies. Hum Mol Genet. 2014 Sep 15;23(R1):R89-98.



- 325 5. Sekula P, Del Greco M F, Pattaro C, Köttgen A. Mendelian Randomization as an Approach to  
326 Assess Causality Using Observational Data. *J Am Soc Nephrol JASN*. 2016 Nov;27(11):3253–  
327 65.
- 328 6. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review. *Res Synth*  
329 *Methods*. 2019 Dec;10(4):486–96.
- 330 7. Su Z, Wan Q. Potential therapeutic targets for Membranous Nephropathy: proteome-wide  
331 Mendelian randomization and colocalization analysis. *Front Immunol*. 2024 Feb 21;15:1342912.
- 332 8. Duan QQ, Wang H, Su WM, Gu XJ, Shen XF, Jiang Z, et al. TBK1, a prioritized drug  
333 repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian  
334 randomization and pharmacological verification in vitro. *BMC Med*. 2024 Mar 5;22(1):96.
- 335 9. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian  
336 Randomization Study of ACLY and Cardiovascular Disease. *N Engl J Med*. 2019 Mar  
337 14;380(11):1033–42.
- 338 10. Holmes MV, Lange LA, Palmer T, Lanktree MB, North KE, Almqvister B, et al. Causal effects  
339 of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.  
340 *Am J Hum Genet*. 2014 Feb 6;94(2):198–208.
- 341 11. Yuan S, Xu F, Li X, Chen J, Zheng J, Mantzoros CS, et al. Plasma proteins and onset of type 2  
342 diabetes and diabetic complications: Proteome-wide Mendelian randomization and colocalization  
343 analyses. *Cell Rep Med*. 2023 Sep 19;4(9):101174.
- 344 12. Yuan S, Larsson SC. Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux  
345 disease: a Mendelian randomization study. *Eur J Epidemiol*. 2022 Jul;37(7):747–54.
- 346 13. Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the  
347 Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsourcing efforts. *Nucleic Acids Res*.  
348 2021 Jan 8;49(D1):D1144–51.
- 349 14. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome  
350 and support for target identification and validation in drug development. *Sci Transl Med*. 2017  
351 Mar 29;9(383):eaag1166.
- 352 15. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and  
353 trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood  
354 gene expression. *Nat Genet*. 2021 Sep;53(9):1300–10.
- 355 16. Xie J, Liu L, Mladkova N, Li Y, Ren H, Wang W, et al. The genetic architecture of membranous  
356 nephropathy and its potential to improve non-invasive diagnosis. *Nat Commun*. 2020 Mar  
357 30;11(1):1600.
- 358 17. Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al. Genome-wide  
359 association analyses define pathogenic signaling pathways and prioritize drug targets for IgA  
360 nephropathy. *Nat Genet*. 2023 Jul;55(7):1091–105.

- 361 18. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53  
362 loci highlight cell types and biological pathways relevant for kidney function. *Nat Commun.*  
363 2016 Jan 21;7:10023.
- 364 19. Köttgen A, Pattaro C. The CKDGen Consortium: ten years of insights into the genetic basis of  
365 kidney function. *Kidney Int.* 2020 Feb;97(2):236–42.
- 366 20. Yuan Z, Zhang Y, Chen P, Liu S, Xin L, Liu C. Long non-coding RNA HLA complex group 18  
367 promotes gastric cancer progression by targeting microRNA-370-3p expression. *J Pharm*  
368 *Pharmacol.* 2022 Feb 1;74(2):250–8.
- 369 21. Chang M, Gao H, Li Y, Ding C, Lu Z, Li D, et al. Identification and analysis of MSC-Exo-  
370 derived LncRNAs related to the regulation of EMT in hypospadias. *BMC Med Genomics.* 2024  
371 Apr 16;17(1):87.
- 372 22. Greco S, Made' A, Mutoli M, Zhang L, Piella SN, Vausort M, et al. HCG18, LEF1AS1 and  
373 lncCEACAM21 as biomarkers of disease severity in the peripheral blood mononuclear cells of  
374 COVID-19 patients. *J Transl Med.* 2023 Oct 26;21(1):758.
- 375 23. Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide  
376 Mendelian randomization mapping the influence of the plasma proteome on complex diseases.  
377 *Nat Genet.* 2020 Oct;52(10):1122–31.
- 378 24. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations with gene  
379 expression complicate GWAS follow-up. *Nat Genet.* 2019 May;51(5):768–9.

380

## 381 **12 Figure legends**

382 Figure 1: Study design.

383 MN: membranous nephropathy; IgAN: IgA nephropathy; CKD: chronic kidney disease; HEIDI  
384 test: heterogeneity in dependent instruments; FDR: false discovery rate; PPH4: posterior probabilities  
385 of hypotheses 4.

386

